Wednesday, July 8, 2026

Patent intelligence · US

US 9821054

Method of vaccination comprising a histone deacetylase inhibitor

granted A61KA61K2039/545A61K31/165A61K31/167
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 11
Applicant portfolio 40
Patent details — US 9821054
Jurisdiction
US
Status
granted
Grant date
Nov 21, 2017
Expiration
Nov 16, 2037
Claims
17
CPC classes
A61K, A61K2039/545, A61K31/165, A61K31/167
View on Google Patents ↗

Quick answer

US 9821054 (Method of vaccination comprising a histone deacetylase inhibitor) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Nov 21, 2017. Expires Nov 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K2039/545, A61K31/165, A61K31/167, A61K31/18, A61K31/19

More from TURNSTONE LIMITED PARTNERSHIP

Related pharmaceutical patents in our USPTO index.

  1. US 12310968

    Chiral diaryl macrocycles and uses thereof

    TURNING POINT THERAPEUTICS, INC. · Expires May 22, 2045

    granted
  2. US 12252488

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Expires Mar 13, 2045

    granted
  3. US 12215105

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Expires Jan 30, 2045

    granted
  4. US 12187739

    Diaryl macrocycle polymorph

    TURNING POINT THERAPEUTICS, INC. · Expires Jan 2, 2045

    granted
  5. US 12071442

    Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists

    Nimbus Saturn, Inc. · Expires Aug 22, 2044

    granted
  6. US 11981684

    Macrocyclic compounds and uses thereof

    TURNING POINT THERAPEUTICS, INC. · Expires May 9, 2044

    granted
  7. US 11926625

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Expires Mar 7, 2044

    granted
  8. US 11802292

    Modified orthopoxvirus vectors

    TURNSTONE BIOLOGICS CORP. · Expires Oct 26, 2043

    granted

Frequently asked questions

What is US patent 9821054?

US 9821054 (Method of vaccination comprising a histone deacetylase inhibitor) is held by TURNSTONE LIMITED PARTNERSHIP. Status: granted. Granted Nov 21, 2017. Expires Nov 16, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9821054?

TURNSTONE LIMITED PARTNERSHIP is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.

When does US 9821054 expire?

Our index shows an expiration date of Nov 16, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.